FDA and CE mark compliant solutions shipped to a global leader in microsurgical systems.

Kopin Corporation (NASDAQ: KOPN) a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical products, has announced, in collaboration with HMDmd, the first production delivery of the CR3 wearable surgical monitor (purpose-built for surgery) to Carl Zeiss Meditec, a top-tier global medical technology company.

The FDA registered and CE certified CR3 wearable surgical monitor is a cutting-edge head-mounted display (HMD) system developed over several years by HMDmd and Kopin. The lightweight, ergonomic design delivers 3-D imagery in full HD resolution and offers benefits for surgeons performing microsurgery, minimally invasive surgery, digital and robotic surgery and interventional medicine. By simply glancing at the head-worn display, surgeons can view live video feeds from surgical instruments and diagnostic images, eliminating the need to repeatedly move their head between a conventional wall or boom mounted monitor and the patient, enabling surgeons to operate with much greater physical comfort.

“Kopin is proud to manufacture a cutting-edge display and optical solution to integrate with the state-of-the-art operating microscopes of Carl Zeiss Meditec, supporting their commitment to precision and innovation,” said Bill Maffucci, SVP Business Development & Strategy. “We believe our advanced display technologies will help drive the next generation of surgical systems, furthering excellence in future microsurgery applications.”

The production of medical-grade head-mounted display systems at Kopin requires rigorous standards for safety, reliability and compliance. This process involves selecting advanced optical and electronic components, implementing superior manufacturing practices, and enforcing strict quality control measures, ensuring a seamless integration into surgical and medical applications.

“The initial delivery of production line devices to Carl Zeiss Meditec marks a significant milestone in our development program, demonstrating considerable progress in both surgical technology and professional adoption,” said John Lyon, CEO, HMDmd. “Kopin and HMDmd will continue to partner and support the evolution of wearable display technology for leading surgical systems companies such as Zeiss.”

As the medical display technology landscape evolves, Kopin and HMDmd will work to remain at the forefront of high-performance wearable solutions, specifically designed and built for medical and surgical professionals worldwide.

About Kopin

Kopin Corporation is a leading developer and provider of innovative display, and application-specific optical solutions sold as critical components and subassemblies for defense, enterprise, professional and consumer products. Kopin’s portfolio includes microdisplays, display modules, eyepiece assemblies, image projection modules, and vehicle mounted and head-mounted display systems that incorporate ultra-small high-resolution Active Matrix Liquid Crystal displays (AMLCD), Ferroelectric Liquid Crystal on Silicon (FLCoS) displays, MicroLED displays (µLED) and Organic Light Emitting Diode (OLED) displays, a variety of optics, and low-power ASICs. For more information, please visit Kopin’s website at www.kopin.com. Kopin is a trademark of Kopin Corporation.

About HMDmd, Inc.

HMDmd is a commercial-stage company, based in Solana Beach, CA. The Company is entirely focused on developing and commercializing advanced wearable display systems specifically designed for microsurgery, minimally invasive surgery, robotic surgery and interventional medicine applications. Our business model is primarily to enter into strategic distribution partnerships with companies planning to integrate OEM or customized versions of HMDmd’s wearable display products into their proprietary surgical and interventional systems.

Follow us on LinkedIn, X and Facebook.

Forward Looking Statements

Statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the safe harbor created by such sections. Words such as “expects,” “believes,” “can,” “will,” “estimates,” and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements. We caution readers not to place undue reliance on any such “forward-looking statements,” which speak only as of the date made, and advise readers that these forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by us that are difficult to predict. These forward-looking statements may include statements with respect to our belief that our advanced display technologies will help drive the next generation of surgical systems, furthering excellence in future microsurgery applications; the expectation that Kopin and HMDmd will continue to partner and support the evolution of wearable display technology for leading surgical systems companies such as Zeiss; and the expectation that, Kopin and HMDmd will work to remain at the forefront of high-performance wearable solutions, specifically designed and built for medical and surgical professionals worldwide. Various factors, some of which are beyond our control, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. All such forward-looking statements, whether written or oral, and whether made by us or on our behalf, are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as may otherwise be required by the federal securities laws. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations are described in Part I, Item 1A. Risk Factors; Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and other parts of our Annual Report on Form 10-K for the fiscal year ended December 28, 2024, or as updated from time to time by our Securities and Exchange Commission filings

View source version on businesswire.com: https://www.businesswire.com/news/home/20250722161686/en/